Therapeutic myocardial angiogenesis.
Armed with an improved understanding of the mediators of angiogenesis, physicians and scientists have made significant efforts at harnessing this naturally occurring process in order to treat patients with a variety of peripheral vascular and coronary ischemic syndromes. There is a growing population of patients with end-stage coronary artery disease (CAD) who are no longer candidates for mechanical revascularization, yet suffer from chronic myocardial ischemia who may benefit from regeneration of the depleted microvasculature.
Renault
Marie-Ange
MA
Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, 303 E Chicago Ave., Tarry 12-703, Chicago, IL 60611, USA.
Losordo
Douglas W
DW
D043925:Angiogenesis Inducing Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D064987:Cell- and Tissue-Based Therapy / Q000379:methods; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D005544:Forecasting; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy*; D009204:Myocardial Revascularization / Q000379:methods*; D018919:Neovascularization, Physiologic / Q000502:physiology
D043925:Angiogenesis Inducing Agents